PDCD1 and neoplasm: In addition to TKI, ICIs such as programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) inhibitor, pembrolizumab, atezolizumab, nivolumab, sintilimab, camrelizumab, tislelizumab and durvalumab, have revolutionized malignancy tumor therapy in recent years.